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abstRact
Objective: to determine risk factors for death in hiV-infected african patients on 
anti-retroviral therapy (aRt). 
Design: Retrospective case-control study. 
Setting: the Moh-usaid-aMpath partnership ambulatory hiV-care clinics in 
western kenya. 
Results: between november 2001 and december 2005 demographic, clinical and 
laboratory data from 527 deceased and 1054 living patients receiving aRt were compared 
to determine independent risk factors for death. Median age at aRt initiation was 38 
versus 36 years for the deceased and living patients respectively (p<0.0148). Median 
time from enrollment at aMpath to initiation of aRt was two weeks for both groups 
while median time on aRt was eight weeks for the deceased and fourty two weeks for 
the living (p<0.0001). patients with cd4 cell counts <100/mm3 were more likely to die 
than those with counts >100/mm3 (hR=1.553. 95% ci (1.156, 2.087), p<0.003). patients 
attending rural clinics had threefold higher risk of dying compared to patients attending 
clinic at a tertiary referral hospital (p<0.0001). Two years after initiating treatment fifty 
percent of non-adherent patients were alive compared to 75% of adherent patients. 
Male gender, Who stage and haemoglobin level <10 grams% were associated with 
time to death while age, marital status, educational level, employment status and 
weight were not. 
Conclusion: profoundly immunosuppressed patients were more likely to die early in 
the course of treatment. also, patients receiving care in rural clinics were at greater 
risk of dying than those receiving care in the tertiary referral hospital. 
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intRoduction 
introduction of anti-retroviral therapy (aRt) 
into middle and low-income countries through 
programmes such as the World health organisation’s 
(Who) “3 by 5” initiative and president’s emergency 
programme for aids Relief (pepfaR) has brought a 
glimmer of hope to africa, the continent most ravaged 
by the hiV pandemic (1-3). through these and other 
initiatives, the number of people receiving aRt in 
middle and low-income countries reached over three 
million people by the end at 2007 (2-4). success at these 
initiatives is largely due to provision of funds for the 
purchase of medications (anti-retroviral drugs and 
antibiotics for treatment of opportunistic infections), 
laboratory equipment and supplies, training of health 
workers and establishment and/or strengthening 
of healthcare delivery systems (5). in spite of such 
commendable progress, an estimated two million 
people die annually from hiV related complications 
worldwide (4, 6).
 the effectiveness at aRt in decreasing hiV 
Rna levels, increasing cd4 cell counts and restoring 
immunity in treatment-naive hiV infected african 
patients has been previously reported in treatment 
initiatives from kenya, senegal, uganda and south 
africa (7-10). in a cohort of patients receiving aRt 
in western kenya, Wools-kaloustian et al found that 
mean cd4 cell counts rose by 160,225 and 295/mm3 
at 12,24 and 36 months respectively. this study also 
documented a mortality rate of 5.4% and a loss to 
following-up rate of 24.5%, much of which was 
attributed to death (7). given the potential for excess 
mortality in this cohort we found it necessary to 
identity risk factors for death after initiating aRt 
in order to target patients who might benefit from 
interventions designed to enhance survival. as such 
we undertook a retrospective case-control study of 
deceased patients within our hiV-care system in 
Western kenya in order to identify factors associated 
with death. the resulting model could also be used 
to adjust analyses or stratify patients by mortality 
risk. 
MateRials and Methods 
Study design: the Moi university institutional 
Research and ethics committee (iRec) and indiana 
university purdue university at indianapolis/ 
clarion institutional Review Board (iRs) approved 
this study. this was a retrospective, case-control study 
employing de-identified data from the prospectively 
compiled electronic medical records of hiV-infected 
patients on aRt at the Moh-usaid-aMpath 
partnership (aMpath). all deceased adult patients 
on ART within the AMPATH system were identified 
as cases while controls were selected from living 
patients on aRt who were enrolled within a month 
of the case. this method of selection was undertaken 
in order to control for the impacts of changes in our 
care programme over time. 
Study site: in november 2001 Moi university school 
of Medicine (MusoM) and Moi teaching and 
Referral hospital (MtRh) in kenya and indiana 
university school of Medicine founded the academic 
Model for the prevention and treatment of hiV 
programme (aMpath, now known as academic 
Model providing access to healthcare) in response 
to the hiV pandemic(11,12). aMpath has enrolled 
>110,000 hiV-infected patients in 46 Ministry of 
health clinics spread throughout western kenya 
(national hiV prevalence rate 71 % (11). core to the 
activities of aMpath is the aMpath Medical Record 
system (aMRs) a fully electronic medical database 
which stores and manages demographic and clinical 
data for all enrolled patients and visits (14-16). the 
aMpath training institute is responsible for the 
initial training and continuing medical education of 
all aMpath staff (17). 
AMPATH Clinical care: patient care is standardised 
within the programme by use of locally developed 
clinical algorithms consistent with the Ministry of 
health, government of kenya and Who guidelines 
for care of the hiV-infected patient (18,19). patient 
medical history including socio-demographic data, 
review of symptoms and Who staging are conducted 
at enrollment. during the follow-up visits data is 
collected on inter-current symptoms and adherence 
assessment is carried out. a complete physical 
examination is done at enrollment and symptom-
directed exams at each follow-up visit. laboratory 
testing (complete blood counts, liver enzymes, renal 
tests and cd4 cell count) is done at baseline and 
repeated every six months. plasma viral load testing 
was not available during the first three years of the 
programme but is currently being used in a subset of 
patients in which aRV failure is suspected. a chest 
radiograph is obtained in all non-pregnant patients 
at enrollment. all clinical and laboratory data are 
recorded on a standard case report form and later 
transcribed into the electronic database (16). 
 a consulting physician attends in the urban clinic 
on a daily basis and once a week in the rural clinics. 
the programme recommends that very ill patients 
be reviewed by the consultant physicians initially 
and followed jointly by the physician and clinical 
officer (mid-level clinician; equivalent to a physician 
assistant). all patients with cd4 cell counts <200/
mm3 are given co-trimoxazole to reduce the risk of 
pneumocystis pneumonia. patients with documented 
allergy to sulfa drugs are given dapsone. all patients 
without signs and symptoms of tuberculosis who have 
a normal chest radiograph are given nine months of 
isoniazid preventative therapy. 
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 aMpath’s standard 1st line aRt regimen 
consists of zidovudine (or stavudine), lamivudine, and 
nevirapine. efavirenz is substituted for nevirapine in 
patients receiving induction therapy for tuberculosis 
in order to decrease risk of hepatotoxicity. no patient 
has ever experienced treatment interruptions due to 
stock shortages. in response to aRt toxicity single 
drug substitutions are made; however, in the face 
of aRt failure a full regimen change is required as 
per local protocol. patients are seen two weeks after 
aRt initiation and then monthly thereafter, at which 
time they receive a months worth of medication. an 
outreach and lost to follow-up programme locates 
patients who fail to return for their scheduled 
appointments. deaths are reported to the clinic from 
the outreach team and/or the patients’ relatives and 
friends. in addition, a research assistant collects data 
on all patients admitted to the wards at MtRh and 
relays information on patient deaths directly to the 
aMpath data management centre. 
Study subjects: data from patients were eligible for 
analysis by this study if the patient was enrolled at 
any of the aMpath clinics and initiated aRt between 
december 2001 and december 2005. patients’ data 
were excluded from the analysis if the patients were 
aRV experienced prior to joining aMpath or if they 
started aRt for pMtct only. Random sampling 
was used to match deceased with living patients in 
a ratio of 1: 2. patients were matched using date of 
aRt initiation (control patients had to have started 
aRt within a month of the case patient) in order 
to account for programmatic changes over time as 
availability of aRt and ancillary services (nutrition, 
outreach, psycho-social support and adherence) have 
expanded over time. 
Data Collection and Management: As a first step, all 
the patients who had died or were lost to follow-
up (defined as missing their clinic appointments 
for at least three months after the initiation aRt) 
were identified retrospectively from the AMRS 
database. Those patients identified as lost to follow-
up and whose locator information was available 
were then actively tracked by the outreach team in 
order to determine those who had died. Vital status 
information obtained by the outreach team was 
added to the AMRS prior to pulling the final dataset 
for analysis. 
 adherence evaluation was based on a self-
reported instrument. patients responded to the 
following question: “during the last seven days, how 
many of her/his aRV pills did the patient take?” the 
available responses were: none, few, half, Most. and 
all. in the present analyses we have dichotomised 
each patient as exhibiting perfect adherence (every 
response at every visit is “all”) versus imperfect 
adherence (any response other than “all” reported 
at even a single visit). 
Statistical methods: descriptive statistics such as mean, 
standard deviation, median and range were calculated 
for the continuous variables. the kruskal-Wallis test 
was used to compare means. frequency tables were 
produced for all categorical variables and these were 
compared via the fisher’s exact test. analyses of time 
until an event were undertaken using the kaplan-
Meier method for the categorical variables. to identify 
independent risk factors for mortality, univariate and 
multivariate cox proportional hazard regression 
models were performed with time from initiation of 
aRt to death as the outcome control patients were 
censored as of the date of their last aMpath clinic 
visit. The regression co-efficient is interpreted as the 
increase of the log-hazard ratio resulting in an increase 
of one unit in the covariate. Mortality rates were 
estimated using kaplan Meier survival analysis. We 
considered as candidat predictors socio-demographic 
characteristics (age, gender, weight, marital status, 
school attendance and employment status); care 
site (urban versus rural) and clinical data identified 
a priori as being likely related to mortality. these 
clinical data included laboratory test results (cd4 cell 
count, alanine aminotransferase and haemoglobin): 
overall adherence to aRVs, Who stage at initiation 
of aRt or the closest assessment measurement prior 
to starting aRt. Because the exact date of death was 
missing for some of the deceased patients, three 
different assumptions were made for the date of 
death: (1) the patient died on the day of his or her last 
appointment, (2) the patient died midway between 
the last appointment and the next scheduled visit and 
(3) the patient died on the date of the next scheduled 
visit (maximum of one month from last visit). Models 
were fitted based on these three assumptions and 
since all the models led to the same conclusions, 
the results of the model where we assume the next 
months clinic visit as the date of death are used. all 
analyses were carried out using stata version 8.0 
(stata corporation, college station, tX). 
Results 
during the study period, a total of 16,134 hiV-
infected adult patients (69% females) were enrolled 
in aMpath of who 8,603 (53%) initiated aRt. in 
the same period, 527 out of the 760 patients (69%) 
documented to have died initiated aRt. all 527 
deceased patients on aRt were successfully matched 
with two patients on aRt who were not known to 
have died as of the date of this analysis. the analysis 
cohort thus contained 527 deceased patients and 1054 
living controls. 
 the characteristics for both groups at the time 
of aRt initiation are shown in table 1.
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table 1
Frequency distribution of various categorical variables by deceased status 
patient characteristic deceased patients living patients p-value
 (n=527)  (n=) 1054)
age at enrolment (years) n=512 n=1019
Median (range) 37.6 (16-77) 36.2 (15-73) 0.0151
gender n=527 n=1054 
Male 241 (46%) 372 (35%) <0.00 12
female 286 (54%) 682 (65%) 
Weight (kg) n=516 n=1042 
Median (range) 49 (22.5-80) 55 (26.5-94) <0.0011 
time from enrolment to n=522 n=1033 
initiation of aRt (wks) 0.071
Median (range) 2.0 (1-140) 2.14(1-163) 
duration of follow-up n=347 n=1054
initiation aRt <0.0011
Median (range) 7.7 (0-110) 42 (0-288) 
cd4 cell count/mmJ at n=427 n=806
initiation of aRt
Median (range) 40 (1-94) 95 (0-1230) <0.0011
haemoglobin (g %) n=401 n=752
Median (range) 10.0(4.4-21.5) 13.8(1.4-19.4) <0.0011
clinic enrolled n=527 n=1054
urban 123 (23%) 445 (42(ycl) <0.0011
Rural 404 (77%) 609 (58%)
aRt adherence n=366 n=974 
adherent 289 (79%) 872 (89.5%) <0.0012
non adherent 77 (21%) 102 (10.5%)
Marital status n=527 n=1054
Married 287 (55%) 598 (57%)
single 240 (45%) 456 (43<10)  0.392
formal education n=439 n=897 
yes 401 (91 %) 836 (93%) 0.222
no 38 (9%) 61 (7%)
employment n=527 n=1054 
yes 175 (33%) 360 (34%) 0.732
no 352 (67%) 694 (66%)
Who stage at start of 
aRt n=410 n=840
stage 1 128 (7%) 214 (25%) 
stage 2 51 (12%) 161 (19%) <0.0011
stage 3 226 (55%) 392 (47%) 
stage 4 105 (26%) 73 (9%)
1 kruskal- Wall is test 
2 fisher’s exact test 
* the missing data represents patients who’s date of death was missing 
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 deceased patients were slightly older than 
controls. the median time from programme 
enrollment to aRt initiation was two weeks for both 
groups. the median duration of follow up while 
on ART was (by virtue of patient selection) five 
times longer for control patients. deceased patients 
had significantly lower weight at ART initiation, 
49 kg versus 55 kg respectively (p<0.0001). other 
characteristics found to be significantly different 
(p<0.0001) at initiation of aRt included: cd4 cell 
count, haemoglobin concentration, location of clinic 
attendance and Who stage. Medication adherence 
during follow-up was also found to be significantly 
different between the two groups (p<0.0001). 
 kaplan Meier plots by initial cd4 cell count 
(dichotomized as <1 00/mm3 versus >1 00/mm3) 
are shown in figure 1.
figure 1
Kaplan-Meier survival estimates for HIV infected adult African,treatment naive patients on anti-retroviral therapy, 
by baseline CD4 counts (<100 versus. 100 cells/ ml
figure 2
Kaplan-Meier survival estimates for HIV-infected adult African, treatment naive patients on anti-retroviral therapy, 
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 the hazard of death is higher for patients started 
on treatment with cd4 cell counts <100/mm3 as 
compared to those starting treatment with cd4 cell 
counts >100/mm3. in a univariate proportional-
hazards regression model it was estimated that 
patients initiating aRt with cd4 cell counts <100/
mm3 had almost twice the risk of dying compared to 
those starting at higher cd4 cell counts (p<0.0001). 
as anticipated, the hazard of death was greater 
for patients with higher Who stage (figure 2). in 
addition, non-adherent patients had a higher hazard 
of death with less than 50% being alive two years after 
initiation aRt compared to close to 75% of adherent 
patients (figure 3). characteristics not found to be 
significantly different between cases and controls 
were marital status, receipt of a formal education 
and employment at the time of enrollment. 
Multi-variable proportional hazards model: a multi-
variable proportional hazards model was fitted 
with the variables that were found to be statistically 
significant in the univariate model at the 20% level. 
table 2: 
Multivariable proportional hazards model: Next scheduled clinic visit date assumed to be the death date for deceased 
patients without a death date 
Variable hazard ratio 95% ci  p-value3 
age at enrollment 1.012 0.999  1.026    0.07
adherence
(adherent versus non
adherent) 0.661 0.475  0.919    0.01
urban versus rural 
clinic 0.356 0.248  0.513    <0.001
gender (female vs. 
male) 0.714 0.546  0.933    0.01
cd4 cell count
(100 vs. > 100/mm3) 1.553 1.156  2.087    0.003
haemoglobin
 (10 vs. >10g%) 1.448 1.112  1.886    0.006
 Who stage 2 vs. 1 1.922 1.086  3.401    0.03
 Who stage 3 vs. 1 2.503 1.533  4.087    <0.001
 Who stage 4 vs. 1 5.332 3.151  9.022    <0.001
figure 3
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 as shown in table 2, the factors associated with 
time to death in this analysis were: gender, location of 
clinic, cd4 cell count, haemoglobin and Who stage 
at initiation of aRt as well as documented adherence 
to medication. holding all other factors constant, male 
patients were found to be one and one-half times 
more likely to die than their female counterparts. 
the hazard for death increases monotonically with 
increasing Who stage from one to four. We observed 
that the hazard for death in patients attending the 
rural clinic was almost three times that for urban 
clinic attendees. similarly, patients initiating aRt with 
haemoglobin less than 10gm% had increased chances 
of dying compared to those with higher haemoglobin 
levels. the hazard for death for adherent patient is 
markedly lower than that for non-adherent patients. 
in this model patients started on aRt with cd4 cell 
counts <1 00/mm3 were found to be one and one half 
times more likely to die compared to those initiating 
at counts >1 00.mm3 
discussion 
While medical, clinical and socio-behavioural-
demographic factors that predict poor outcomes in 
patients on aRt have been documented in different 
populations from around the world, (20-33) to our 
knowledge, this study is the first to do so in a cohort 
of kenyan adult patients on aRt. We found that male 
gender, low cd4 cell count, higher Who stage and 
low haemoglobin concentration at initiation of aRt, 
poor adherence during treatment and clinic location 
(urban compared to rural clinic) are significant 
independent risk factors for mortality. the fact 
that male gender is a risk factor for mortality is not 
surprising given our previous study which found that 
men tended to present with higher Who stages and 
lower cd4 cell counts than women (7). We theorise 
that the traditional male role in kenyan society which 
discourages the show of weakness leads to delays in 
men seeking healthcare thus placing them at higher 
risk for death. in addition concerns about stigma and 
blame may also contribute to delays in seeking care. 
nevertheless, the fact that gender was found to be an 
independent risk factor in the multi-variable model, 
even after adjusting for cd4 count and Who stage at 
initiation of aRt, means that there are other factors, 
not measured in this study, that are associated with 
the male role in kenya. a possible explanation for 
the higher mortality rates in men is the increased 
use of alcohol in this group when compared to their 
female counterparts, a factor that has previously been 
associated with worse hiV outcomes (34). 
 as expected, low cd4 cell count and late Who 
stage were significantly associated with the risk of 
death. in addition, individuals who succumbed 
to this disease died a median of eight weeks after 
initiation of therapy. Whether these deaths are 
related to opportunistic infections acquired prior to 
immune reconstitution, the immune reconstitution 
inflammatory syndrome or drug toxicity cannot be 
determined from our current data. however these 
data do suggest the need for earlier identification of 
hiV infected individuals and more timely initiation 
of aRt and 01 prophylaxis and/or treatment. 
 Accomplishing the goal of early identification 
will require a multi-pronged approach including 
de-stigmatisation of HIV within the community; 
strengthening of voluntary counselling and testing 
services; and introduction of diagnostic HIV testing in 
tuberculosis and sexually transmitted infection clinics 
as well as on the hospital wards. it will also require an 
increase in the number of healthcare workers trained 
to identify and treat hiV and its complications as 
well as the number of healthcare facilities equipped 
to provide anti-retroviral care. 
 the association between adherence and hiV 
progression has been well documented in previous 
studies (35-38). We found that the use of a single 
item to assess self-reported patient adherence was 
predictive of mortality. this is consistent with our 
previous finding that this item is predictive of CD4 
cell response to anti-retroviral therapy (7). More 
detailed studies to establish how levels of adherence 
influence clinical response to ART as well as studies 
aimed at identifying factors that contribute to poor 
adherence are currently underway within aMpath. 
however, it is clear that closer attention must be paid 
to adherence issues and that interventions targeted at 
improving adherence are likely to decrease mortality 
rates in individuals who initiate aRt. 
 significant differences in mortality rates 
recorded in urban and rural sites may be associated 
with the cadre of health workers providing care. 
in the urban clinic physicians play an active day-
to-day role whereas in the rural sites consulting 
physician only visit once per week. a greater level of 
laboratory, radiological and other diagnostic support 
at the MtRh clinic as well as the presence of more 
extensive in-patient facilities may also contribute 
to the differential mortality rates. it is also possible 
that the distance patients have to travel to clinic 
for care may impact mortality since patients in the 
rural clinics have to travel longer distances than 
their urban counterparts, most of who live close to 
the hospital. another possible explanation for the 
mortality differences is differential reporting. Because 
the rural communities are smaller and have much 
closer ties to the health centre staff than do urban 
patients with MtRh staff, it is possible that deaths are 
more likely to be reported at the rural centres while 
at the urban clinic these patients may be labeled as 
lost to follow-up. further study is necessary in order 
to determine which explanation for the urban-rural 
divide is valid. Since difference in staffing for rural 
health centres impact most sub-saharan africa, 
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confirmation of this as an issue would indicate the 
need to find a solution. Such a solution might include 
the training of more physicians, identifying ways to 
retain physicians in rural areas, improving training 
for clinical officers, increasing back-up and support of 
clinical officer through web-based or telephone-based 
consultation with physicians or the development of 
clinical decision support systems (39). 
 The limitations of this study include significant 
dependence on a passive reporting system for 
mortality, which does not allow for the capture of all 
deaths within this system. this study was designed 
as a case-control study rather than a cohort study in 
order to counter this issue. the other limitation of 
this study is the absence of data on cause of death. as 
such it is not possible to know if deaths were related 
to opportunistic infections, drug toxicity or immune 
reconstitution syndrome. 
In conclusion we confirm that advanced hiV 
infection (based on Who stage and cd4 cell count) at 
initiation of aRt is associated with early mortality in a 
population of patients in western Kenya. This finding 
substantiates the need for early identification and 
treatment of hiV infected individuals in sub-saharan 
africa. attention needs to be focused on those patients 
presenting with lowest cd4 cell counts to understand 
causes of death and develop intervention methods. 
in addition it demonstrates the need for continued 
commitment from the international community to 
provide funds to establish and support hiV treatment 
services in resource poor settings. We also identify 
male gender as a risk factor for death due to hiV 
infection even after the initiation of aRt. this indicates 
a need to improve our understanding of male health 
care seeking behaviors within our cultural context 
as well as a need to design healthcare interventions 
specifically targeted toward men. Last, but not least, 
the finding that patients attending rural clinics are at 
greater risk of dying than those attending the referral 
centre call for more operations-type research on the 
subject matter. such research might determine the 
factors that cause such differentials in mortality, 
hence provide useful information for mitigating 
interventions to be put in place. 
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